It is probably worthy of note that press articles on the treatment of aging via senolytic therapies are becoming similar in tone and content to press articles on any other active field of medical development. Take this example, publicity for Unity Biotechnology and their work on senolytic therapies to clear senescent cells from old tissues and thus remove one of the contributing causes of aging and age-related disease. It is formatted as a discussion of trials, funding, and this company or that company, this lab or that lab. It exhibits little of the breathless nonsense as to why we shouldn’t address aging and its consequences, a regular feature of the past decade of coverage, and is more a matter of business as usual. Whether this heralds a sweeping change in the way in which the world views aging is anyone’s guess, but the existence of major investment and sizable companies working on therapies for aging does serve to make it increasingly challenging to be a naysayer on the topic of extended healthy longevity without appearing foolish.
Osteoarthritis is the first disease Unity Biotechnology is tackling, and that one disease represents a huge opportunity: By 2026, the market
Article originally posted at